News from Syndax Pharmaceuticals, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

20 Jan, 2016, 08:00 ET Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, announced...


03 Dec, 2015, 08:00 ET Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


01 Dec, 2015, 08:00 ET Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


16 Sep, 2015, 08:00 ET Syndax To Present At Two Upcoming Scientific Conferences

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


01 Sep, 2015, 08:00 ET Michael Meyers, M.D., Ph.D., Joins Syndax Pharmaceuticals As SVP And Chief Development Officer

 Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy in multiple...


05 Feb, 2015, 12:00 ET Syndax to Present at 2015 BIO CEO & Investor Conference

 Syndax Pharmaceuticals, Inc., today announced that chief executive officer, Arlene Morris, will be presenting a corporate overview at the 17th...


07 Jan, 2015, 19:00 ET Kyowa Hakko Kirin and Syndax Announce an Exclusive License Agreement to Develop and Commercialize Entinostat in Japan and Korea

 Kyowa Hakko Kirin Co., Ltd., (Headquarters: Chiyoda-ku, Tokyo; president and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") and Syndax...


27 May, 2014, 08:00 ET Syndax Announces Presentation of Entinostat Data in Two Posters at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

 Syndax Pharmaceuticals, Inc., today announced that clinical trial data on entinostat will be presented in two posters during the 50th Annual...


27 Mar, 2014, 18:43 ET Syndax Files Registration Statement for Proposed Initial Public Offering

 Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...


13 Feb, 2014, 08:00 ET Syndax Announces NCI and FDA Reach Agreement on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Entinostat in Patients with Advanced ER+ Breast Cancer

Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has...


01 Nov, 2013, 08:00 ET Syndax Promotes John S. Pallies to Chief Financial Officer and Dr. Peter Ordentlich to Chief Technology Officer

Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and...


14 May, 2013, 08:30 ET Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on developing novel combination epigenetic strategies to treat cancers...


16 May, 2012, 08:30 ET Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...


30 Apr, 2012, 08:30 ET Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology

 Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors,...


18 Apr, 2012, 09:53 ET Syndax Pharmaceuticals Appoints Arlene Morris as CEO

 Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies,...


09 Apr, 2012, 08:30 ET Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD...


05 Apr, 2012, 08:30 ET Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced Arthur M. Pappas will join the board of...


29 Mar, 2012, 08:30 ET Syndax Pharmaceuticals to Present at Upcoming Conferences

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that management will present at the following upcoming...


09 Feb, 2012, 09:00 ET Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer Institute have...


07 Feb, 2012, 08:30 ET Syndax Pharmaceuticals to Present at Upcoming Conferences

 Syndax Pharmaceuticals, Inc., a late-stage epigenetics oncology company, announced that management will present at the following upcoming...


11 Dec, 2011, 21:00 ET Entinostat Demonstrates Activity in Hodgkin's Lymphoma

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small...


07 Dec, 2011, 18:00 ET Survival Benefit With Syndax Pharmaceuticals' Entinostat Maintained in Women with Advanced Breast Cancer

 Syndax Pharmaceuticals, Inc. announced today that, with a 23-month patient follow up of ENCORE 301, a multicenter, randomized,...


01 Dec, 2011, 08:30 ET Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences

 Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that multiple data presentations from phase 2...


13 Nov, 2011, 10:00 ET Syndax Pharmaceuticals Presents Data Linking Pharmacodynamic Marker to Clinical Benefit in Advanced Breast Cancer Patients

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients...


02 Nov, 2011, 08:58 ET Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced today that pharmacodynamic analysis in a subset of patients...